摘要
目的：研究巨噬细胞炎症蛋白-1α（MIP-1α）、骨硬化蛋白与多发性骨髓瘤（MM）并发骨髓瘤骨病（MBD）的关系。方法以52例MM患者为观察组，其中无骨病者9例，有骨病者43例；MBD分级：0级9例、1级8例、2级21例、3级14例；选取28例健康体检者为对照组。分析MIP-1α、骨硬化蛋白与MBD的关系。结果观察组MIP-1α及骨硬化蛋白分别为（158．43±78．75）pg／mL、（0．62±0．24）pg／mL，均明显高于对照组的（52．46±21．35）pg／mL、（0．31±0．14）pg／mL（t＝9．635，P＜0．05；t＝8．844，P＜0．05）；MIP-1α、骨硬化蛋白随临床分期增加而逐渐升高（P＜0．05）；有骨病组MIP-1α及骨硬化蛋白分别为（175．55±62．75）pg／mL、（0.84±0．54）pg／mL，明显高于无骨病组的（89．83±41．57）pg／mL、（0．42±0．25）pg／mL（t＝7．665，P＜0．05；t＝6．834，P＜0．05）；MIP-1α和骨硬化蛋白与骨病分级存在相关性（r＝0．572，P＜0．05；r＝0．683，P＜0．05）。MIP-1α与骨硬化蛋白呈正相关（r＝0．522，P＜0．05）。结论 MM患者MIP-1α及骨硬化蛋白水平明显升高，两者均与MBD呈正相关，且两者之间也具有明显相关性，联合检测可作为评估MBD的重要指标。
Objective To investigate the relationship between macrophage inflammatory protein 1-α（MIP-1α） ,sclerostin and multiple myeloma bone disease（MBD） .Methods 52 patients with multiple myeloma were selected as the observation group,among them,9 cases without MBD,43 cases with MBD;MBD grade：9 cases with grade 0,8 cases with grade 1,21 cases with grade 2,14 cases with grade 3.25 healthy examinee were selected as the control group.MIP-1αand sclerostin were observed.Results MIP-1α,sclerostin in the observation group[（158.43 ± 78.75）pg/mL,（0.62 ±0.24）pg/mL] were higher than those in the control group[（52.46 ±21.35）pg/mL,（0.31 ± 0.14）pg/mL]（t =9.635,P 〈0.05;t =8.844,P 〈0.05）;MIP-1α,sclerostin of MBD patients[（175.55 ± 62.75）pg/mL,（0.84 ±0.54）pg/mL]were higher than those of non MBD patients[（89.83 ±41.57）pg/mL,（0.42 ± 0.25）pg/mL]（t=7.665,P〈0.05;t=6.834,P〈0.05）.There were positive relation between MIP-1α,sclerostin and the grade of MBD（r=0.572,P〈0.05;r=0.683,P〈0.05）.There was positive relation between the expressions of MIP-1αand sclerostin（r =0.522,P 〈0.05）.Conclusion MIP-1αand sclerostin of patients with MM have increased.There is a significant relation between MIP-1α, sclerostin and MBD.United detection of MIP-1αand sclerostin may be an index used as evaluation of MBD.
出处
《中国基层医药》
CAS
2014年第23期3540-3542,共3页
Chinese Journal of Primary Medicine and Pharmacy
